Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?

To: Tech Master who wrote (13889)	5/18/1998 9:09:00 AM
From: Tech Master	Respond to of 17305

Monday May 18, 8:15 am Eastern Time Company Press Release Cheung Laboratories Name and Symbol Change Effective Immediately Celsion Corporation Begins Trading Today Under CELN COLUMBIA, Md.--(BW HealthWire)--May 18, 1998--Cheung Laboratories, Inc. (OTC BB:CGLB - news) today announced that the Company will begin trading today under the name Celsion Corporation and stock symbol CELN. The name change reflects the Company's primary business of using deep focused heat to kill cancer cells and was approved at the annual shareholders' meeting in April 1998. ''Adopting the name Celsion redefines and sets the stage for the Company as we prepare to enter clinical human trials to demonstrate our system's effectiveness in treating breast cancer and benign prostatic hyperplasia (BPH),'' stated Company President and CEO Spencer Volk. Breast Cancer Treatment System In May 1998, researchers from Hammersmith Hospital in London, England successfully concluded an initial study of the Company's breast cancer treatment system in a large animal model. These findings further confirmed the system's safety and effectiveness as established by Harvard's Massachusetts General Hospital (MGH) in Boston, Massachusetts where an initial safety study, conducted in March 1997, demonstrated the system's ability to heat deep tumors without burning superficial tissues and resulted in the FDA Pre Market Approval (PMA) for commercialization in September 1997. Additional preclinical evaluations to demonstrate the feasibility of using the system to ablate breast and other tumors have recently been initiated at MGH. Data from MGH to confirm tumor ablation is expected by the end of June 1998. The hospitals which will conduct clinical trials on breast tumor ablation include Hammersmith and MGH as well as Columbia HCA Healthcare's JFK Medical Center in West Palm Beach, Florida. Benign Prostatic Hyperplasia (BPH) Treatment System Animal testing of the Company's BPH treatment system was completed in February 1998 at the Montefiore Medical Center in New York, and an Investigational Device Exemption (IDE) application was filed by the Company with the FDA in April 1998. Receipt of the IDE will allow the Company to begin patient studies to obtain data demonstrating the system's safety and efficacy in order to apply for a PMA for commercialization. The Company has made arrangements with the Montefiore Hospital and the Walter Reed Army Medical Research Institute in Washington, D.C. as initial clinical sites for the BPH system. Celsion Corporation, formerly Cheung Laboratories, Inc., is a research and development company dedicated to commercializing medical treatment systems for cancer and benign prostatic hyperplasia (BPH) utilizing deep focused heat delivered by patented microwave technology. Celsion is presently working with leading institutions to develop its focused heat treatments, including Massachusetts General Hospital (MGH), Montefiore Medical Center, and Duke University in the United States, and Hammersmith Hospital and Oxford University in England. -0- Forward-looking statements in this release are made pursuant to the ''safe harbor'' provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, possible changes in cost of materials, expense items, capital expenditures, capital structure, and other financial items; introduction of new products and possible acquisitions of assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.